Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$6.4MFederal grants as PI17 awards
0Patents grantedNone matched
218Papers17,200 citations
Federal awards and patents by year
AwardsPatents
17 awards · $6.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 12, 2025 | NIH | SBIR Phase I Development of Safe and Rapid Reporter Viruses for Studying Pathogenic and Pandemic Viruses | $289K | INTEGRAL MOLECULAR INC |
| Jun 25, 2024 | NIH | SBIR Phase I Development of Safe and Rapid Reporter Viruses for Studying Pathogenic and Pandemic Viruses | $289K | INTEGRAL MOLECULAR INC |
| May 4, 2023 | NIH | SBIR Phase I Identifying Regulators of Cellular Aging that can Prevent Alzheimer's Disease | $89K | INTEGRAL MOLECULAR INC |
| Jun 15, 2022 | NIH | SBIR Phase II Next Generation Specificity Screening for Biotherapeutics using an Extracellular Proteome Array | $204K | INTEGRAL MOLECULAR INC |
| May 18, 2022 | NIH | SBIR Phase I Identifying Regulators of Cellular Aging that can Prevent Alzheimer's Disease | $359K | INTEGRAL MOLECULAR INC |
| Jun 25, 2021 | NIH | SBIR Phase II Next Generation Specificity Screening for Biotherapeutics using an Extracellular Proteome Array | $502K | INTEGRAL MOLECULAR INC |
| Jun 30, 2020 | NIH | SBIR Phase II Next Generation Specificity Screening for Biotherapeutics using an Extracellular Proteome Array | $934K | INTEGRAL MOLECULAR INC |
| May 1, 2020 | NIH | SBIR Phase II Development of CB1 Monoclonal Antibodies for Treating NASH | $339K | INTEGRAL MOLECULAR INC |
| Apr 19, 2019 | NIH | SBIR Phase I Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases | $204K | INTEGRAL MOLECULAR INC |
| Apr 19, 2019 | NIH | SBIR Phase II Development of CB1 Monoclonal Antibodies for Treating NASH | $697K | INTEGRAL MOLECULAR INC |
| Dec 22, 2018 | NIH | SBIR Phase II High-throughput Identification of Membrane Protein MAbs | $262K | INTEGRAL MOLECULAR INC |
| Sep 10, 2018 | NIH | SBIR Phase II Development of CB1 Monoclonal Antibodies for Treating NASH | $438K | INTEGRAL MOLECULAR INC |
| Aug 27, 2018 | NIH | SBIR Phase II High-throughput Identification of Membrane Protein MAbs | $100K | INTEGRAL MOLECULAR INC |
| Aug 17, 2018 | NIH | SBIR Phase I Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases | $211K | INTEGRAL MOLECULAR INC |
| Dec 25, 2017 | NIH | SBIR Phase II High-throughput Identification of Membrane Protein MAbs | $525K | INTEGRAL MOLECULAR INC |
| Jan 10, 2017 | NIH | SBIR Phase II High-throughput Identification of Membrane Protein MAbs | $686K | INTEGRAL MOLECULAR INC |
| Jan 23, 2015 | NIH | SBIR Phase I High-throughput Identification of Membrane Protein MAbs | $225K | INTEGRAL MOLECULAR INC |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#165
Awards as PI#29
Patents#273
Companies
- INTEGRAL MOLECULAR INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.